JMA Journal

Figure 1. Study scheme.
The ARNI and ARB groups enrolled 27 and 28 patients, respectively. In the ARNI group, all patients had been treated with olmesartan prior to ARNI therapy. The initial ARNI dose was 100 mg for all patients and titrated according to blood pressure. In the ARB group, 13 patients used enalapril and 15 patients did not use ACEI or ARB prior to ARB therapy. Olmesartan and azilsartan were used in 25 and 3 patients, respectively. Both olmesartan and azilsartan had a median dose of 20 mg at initiation, and the dose was increased according to blood pressure.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor.

Figure 2. Efficacy analysis based on N-terminal pro B-type natriuretic peptide.
There was no significant change in the NT-proBNP levels.
NT-proBNP, N-terminal pro B-type natriuretic peptide.

Figure 3. Efficacy analysis based on nutritional status index and related laboratory data.
There was a significant decrease in the CONUT score at 4 weeks. There were no significant changes in the GNRI and BMI. Regarding nutritional status, there were no significant changes in the total lymphocyte count and TC; however, the albumin levels significantly increased at 4 weeks.
BMI, body mass index; CONUT, controlling nutritional status; GNRI, geriatric nutritional risk index.

Figure 4. Safety analysis using renal function, potassium, and systolic blood pressure.
None of the patients exhibited worsening renal function. No significant increase in potassium levels was observed. Furthermore, there was no significant change in systolic blood pressure after adjusting the ARNI dose.
ARNI, angiotensin receptor-neprilysin inhibitor; eGFR, estimated glomerular filtration rate.